Predicting the risk of neutropenic complications and reduced dose intensity in patients with early-stage breast cancer (ESBC): Results from a prospective nationwide registry.

被引：0
|
作者：
Lyman, GH
Crawford, J
Dale, DC
Wolff, DA
Culakova, E
机构：
[1] Univ Rochester, Med Ctr, Rochester, NY 14627 USA
[2] Duke Univ, Med Ctr, Durham, NC USA
[3] Univ Washington, Med Ctr, Seattle, WA 98195 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
776
引用
下载
收藏
页码：70S / 70S
页数：1
相关论文
共 50 条
  • [1] Factors associated with reduced dose intensity in patients receiving adjuvant chemotherapy for early-stage breast cancer (ESBC).
    Lyman, GH
    Wolff, DA
    Culakova, E
    Poniewierski, A
    Dale, DC
    Crawford, J
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S60 - S60
  • [2] Predicting the risk of neutropenic complications and reduced dose intensity in patients with malignant lymphoma: Results from a prospective study.
    Dale, DC
    Crawford, J
    Wolff, DA
    Poniewierski, MS
    Culakova, E
    Lyman, GH
    BLOOD, 2004, 104 (11) : 234B - 234B
  • [3] Predictors of reduced relative dose intensity (RDI) in patients with early-stage breast cancer (ESBC) receiving adjuvant chemotherapy (CT).
    Lyman, GH
    Crawford, J
    Dale, DC
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S49 - S49
  • [4] A prospective risk model for neutropenic complications in early-stage breast cancer patients receiving adjuvant chemotherapy.
    Lyman, GH
    Kuderer, NM
    Shayne, M
    Dale, DC
    Wolff, D
    Culakova, E
    Poniewierski, MS
    Crawford, J
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S125 - S126
  • [5] Personalizing Supportive Care: A Clinical Prediction Model for Neutropenic Complications in Patients with Early-Stage Breast Cancer (ESBC) Receiving Intermediate Risk Chemotherapy.
    Kuderer, N. M.
    Culakova, E.
    Poniewierski, M. S.
    Crawford, J.
    Dale, D.
    Lyman, G. H.
    CANCER RESEARCH, 2011, 71
  • [6] Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy
    Michelle Shayne
    Jeffrey Crawford
    David C. Dale
    Eva Culakova
    Gary H. Lyman
    Breast Cancer Research and Treatment, 2006, 100 : 255 - 262
  • [7] Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy
    Shayne, Michelle
    Crawford, Jeffrey
    Dale, David C.
    Culakova, Eva
    Lyman, Gary H.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 (03) : 255 - 262
  • [8] Prospective validation of a risk model for first cycle neutropenic complications in early-stage breast cancer patients receiving adjuvant chemotherapy.
    Lyman, G. H.
    Kuderer, N. M.
    Crawford, J.
    Wolff, D. A.
    Culakova, E.
    Poniewierski, M. S.
    Dale, D. C.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S283 - S284
  • [9] Reduced chemotherapy dose intensity in patients with ovarian cancer: Results from a prospective nationwide study
    Poniewierski, M. S.
    Crawford, J.
    Dale, D. C.
    Culakova, E.
    Kuderer, N. M.
    Wolff, D. A.
    Lyman, G. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [10] Risk of neutropenic complications based on a prospective nationwide registry of cancer patients initiating systematic chemotherapy.
    Wolff, DA
    Crawford, J
    Dale, DC
    Poniewierski, MS
    Lyman, GH
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 549S - 549S
12345